Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at $0.10. Each Unit will consist of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years...
2025-06-26 9:00 AM EDT
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities...
2025-06-17 8:41 AM EDT
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) 2025 World Congress in Freiburg, Germany.Hemostemix's presentation highlights the company's clinical pipeline, and its innovation to finance the company non dilutively from the forward sale of therapy convertible debentures...
2025-05-20 9:00 AM EDT
Hemostemix Closes Private Placement of USD $336,500 at $0.295 per Share
Calgary, Alberta--(Newsfile Corp. - May 12, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), per the Company's February 4, 2025 news release, closed the previously announced USD $336,500 non-brokered private placement, issuing 1,634,466 Common Shares at CAD $0.295 each to CytoImmune Therapeutics LLC, following the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. Per Policy 4.1., Cytoimmune Therapeutics LLC is arm's length to the Company and...
2025-05-12 9:00 AM EDT
Hemostemix at Invest Stuttgart
Calgary, Alberta--(Newsfile Corp. - May 8, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is poised to make a significant impact at Invest Stuttgart 2025, Germany's premier finance and investment conference, taking place from May 9-10, 2025 at Messe Stuttgart. The event attracts thousands of investors, financial professionals, and innovators, offering a dynamic platform for Hemostemix to showcase its advancements and connect with potential ACP-01 clients and new shareholders.Hemostemix: A Leader in Autologous Stem...
2025-05-08 9:12 AM EDT
Hemostemix Engages PatentVest to Strengthen its Global Patent Portfolio
Calgary, Alberta--(Newsfile Corp. - April 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) a leader in the development of autologous stem cell therapy for the treatment of cardiovascular diseases, announces its partnership with PatentVest. PatentVest, a subsidiary of MDB Capital (NASDAQ: MDBH), is a premier intellectual property strategy and patent prosecution firm specializing in life sciences. The engagement underscores Hemostemix's commitment to expanding its intellectual property portfolio to drive innovation and shareholder value. PatentVest will provide Hemostemix...
2025-04-23 11:53 AM EDT
Hemostemix's Pitch to Wall Street: ACP-01 Vascular Dementia Trial will Generate $5,365,000, Capture Data, as a Phase 1 Clinical Trial
Calgary, Alberta--(Newsfile Corp. - March 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, pitched the treatment of Vascular Dementia with ACP-01 to Wall Street."The specificity of ACP-01 in promotion of angiogenesis, the molecular up-regulation of brain neurotrophic factors, and specific chemokines, strongly suggest ACP-01 may be efficacious as a treatment for vascular dementia," stated Dr....
2025-03-17 10:28 AM EDT
Hemostemix and FireFly Neuroscience's Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
Calgary, Alberta--(Newsfile Corp. - March 6, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell company that has safely treated 498 patients for various forms of cardiovascular disease, including vascular dementia, announces its collaboration with Firefly Neuroscience, Inc. (NASDAQ: AIFF) ("Firefly"), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Hemostemix and Firefly will study brain wave activity in up...
2025-03-06 7:30 AM EST
Hemostemix Sells Its 23rd ACP-01 Therapy Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - March 5, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announces the sale of 15 ACP-01 Therapy Convertible Debentures for proceeds of USD $517,230, subject to the approval of the TSXV...
2025-03-05 7:45 AM EST
RETRANSMISSION: Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its autologous stem cell market, and create a cost-effective allogenic stem...
2025-02-20 6:05 AM EST
Hemostemix Licenses CytoImmune's BioReactor Technologies
Calgary, Alberta--(Newsfile Corp. - February 19, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce a strategic breakthrough that secures its leadership position in the global stem cell market. By securing an arm's length perpetual, royalty-free global license to CytoImmune's Bioreactor stem cell technologies, Hemostemix has established an economic and competitive advantage that enhances its ability to scale ACP-01, protect its autologous stem cell market, and create a cost-effective allogenic stem...
2025-02-19 3:24 PM EST
Hemostemix Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - February 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that, at the request of the Canadian Investment Regulatory Organization ("CIRO"), it is issuing this news release to clarify and provide additional information regarding its previous announcement dated February 10, 2025.On February 10, 2025, Hemostemix announced the engagement of Proconsul Capital Ltd. to provide investor relations services. The Company wishes to provide the following additional details in accordance with...
2025-02-13 8:09 PM EST
Hemostemix PR Inc. Congratulates Luis Munoz Marin International Airport on Achieving CEIV Pharma Certification
San Juan, Puerto Rico--(Newsfile Corp. - February 11, 2025) - Hemostemix PR Inc. proudly congratulates Luis Muñoz Marín International Airport (SJU) on achieving the prestigious CEIV Pharma Certification from the International Air Transport Association (IATA). This milestone reinforces Puerto Rico's status as a global leader in the logistics of biologics and pharmaceutical products.The CEIV Pharma Certification ensures the highest standards in the handling, storage, and transportation of biologics and pharmaceutical products, meeting rigorous international criteria for quality and safety. With...
2025-02-11 9:43 AM EST
Hemostemix Contracts ProConsul to Ramp up Engagement with New Investors
Calgary, Alberta--(Newsfile Corp. - February 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to announce that it has engaged ProConsul Capital Ltd. ("ProConsul"), to provide investment marketing consulting services (the "Services") commencing February 6th, 2025. In consideration for the Services, the Company will pay a fee of $6,000/month and has agreed to grant stock options to ProConsul. The number and terms of the stock options will be determined at...
2025-02-10 10:48 AM EST
CytoImmune Subscribes for 1,634,466 Hemostemix Common Shares
Calgary, Alberta--(Newsfile Corp. - February 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is delighted to announce that CytoImmune is subscribing USD $336,500 to a non-brokered private placement of Common Shares at today's closing price of $0.295 ($336,500 / $0.69789 = $482,167.68) (1,634,466 Common Shares), subject to the approval of the TSXV Exchange, in keeping with their guidance as announced on January 9, 2025. "The Hemostemix technology transfer was highlighted at CytoImmune's...
2025-02-04 5:16 PM EST
Hemostemix Expands to the Dominican Republic
Calgary, Alberta--(Newsfile Corp. - February 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its continued expansion, as the Company brings its revolutionary ACP-01 therapy back to the Dominican Republic. Hemostemix has posted an update on Social Media, sharing an inside look at its latest initiative in the Dominican Republic, with a team of cardiologists who have the capacity to treat 110 patients per month. This team of cardiologists...
2025-02-03 12:57 PM EST
Hemostemix Announces First Sales Orders for ACP-01
Calgary, Alberta--(Newsfile Corp. - January 29, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its sales of ACP-01 Treatments are gaining traction, following its social media campaign and presentations in Puerto Rico. "Advanced sales of ACP-01 enables the purchaser/patient to understand if they are patient one, 10, or 500, and that certainty is helpful," stated Thomas Smeenk, Hemostemix, CEO. "Advanced sales enables Hemostemix to schedule...
2025-01-29 2:11 PM EST
Hemostemix Up-lists to TradeGateExchange in Germany
Calgary, Alberta--(Newsfile Corp. - January 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares commenced trading on the TradeGateExchange.De under symbol 2VF0 today, January 27, 2025."Listing on the TradeGateExchange.De enables Hemostemix to investors in the Europe, the EU, UK, to buy into their Fountain of Youth and longevity, directly. As management and directors, we have invested greater than $9.1 Million in Hemostemix's ...
2025-01-27 2:37 PM EST
Hemostemix Up-Lists to OTCQB While it Presents its Global Scale-Up Strategy at Two Investor Conferences in Puerto Rico
Calgary, Alberta--(Newsfile Corp. - January 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is very pleased to announce that its shares will commence trading on the OTCQB under symbol HMTXF today, January 23, 2025, while the Company presents "Welcome to Your Fountain of Youth!" at the Sequire Investor Summit at 11:00 a.m."Listing on the OTCQB enables US investors to buy into their 'Fountain of Youth' and longevity, directly. As an investor...
2025-01-23 8:27 AM EST
Hemostemix Announces Grant of Stock Options
Calgary, Alberta--(Newsfile Corp. - January 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on January 22, 2025, subject to regulatory approval, a total of 2,085,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 1,815,000 vest immediately and 270,000 vest as to 50% on January...
2025-01-22 12:14 AM EST